Simian–Human immunodeficiency viruses expressing chimeric subtype B/C Vpu proteins demonstrate the importance of the amino terminal and transmembrane domains in the rate of CD4+ T cell loss in macaques  by Ruiz, Autumn et al.
Virology 435 (2013) 395–405Contents lists available at SciVerse ScienceDirectVirology0042-68
http://d
n Corr
E-mjournal homepage: www.elsevier.com/locate/yviroSimian–Human immunodeﬁciency viruses expressing chimeric subtype B/C
Vpu proteins demonstrate the importance of the amino terminal and
transmembrane domains in the rate of CD4þ T cell loss in macaquesAutumn Ruiz a, Kimberly Schmitt a, Nathan Culley b, Edward B. Stephens a,n
a Department of Microbiology, Molecular Genetics, and Immunology, University of Kansas Medical Center, Kansas City, KS 66160, USA
b Laboratory Animal Resources, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USAa r t i c l e i n f o
Article history:
Received 23 July 2012
Returned to author for revisions
20 August 2012
Accepted 20 October 2012
Available online 5 December 2012
Keywords:
Vpu
Simian–human immunodeﬁciency virus
SHIV
Pathogenesis
Transmembrane domain
CD4þ T cell loss
Subtype C HIV-1
Chimeric Vpu protein22/$ - see front matter & 2012 Elsevier Inc. A
x.doi.org/10.1016/j.virol.2012.10.030
esponding author. Fax: þ1 913 588 7928.
ail address: estephen@kumc.edu (E.B. Stephena b s t r a c t
Previously, we reported that simian–human immunodeﬁciency viruses expressing either the lab
adapted subtype B (SHIVKU-1bMC33) or subtype C (SHIVSCVpu) Vpu proteins of human immunodeﬁciency
virus type 1 (HIV-1) had different rates of CD4þ T cell loss following inoculation into macaques. In this
study, we have generated SHIVs that express either the subtype B or subtype C N-terminal (NTD) and
transmembrane (TMD) domains and the opposing cytoplasmic domain (SHIVVpuBC, SHIVVpuCB). In
culture systems, SHIVVpuBC replicated faster than SHIVVpuCB while both proteins exhibited similar ability
to down-modulate CD4 surface expression. Following inoculation into macaques, SHIVVpuBC resulted in
rapid CD4þ T cell loss similar to the parental SHIVKU-1bMC33, while the rate of CD4
þ T cell loss in those
inoculated with SHIVVpuCB was intermediate of SHIVSCVpu and SHIVKU-1bMC33. These results emphasize
the importance of the Vpu NTD/TMD region in the rate of CD4þ T cell loss in the pathogenic X4 SHIV/
macaque model.
& 2012 Elsevier Inc. All rights reserved.Introduction
The human immunodeﬁciency virus type I (HIV-1) Vpu protein
is a small integral membrane phosphoprotein that augments
HIV-1 pathogenesis by down-modulating CD4 surface expression
and enhancing virus release from infected cells. Vpu consists of a
short N-terminal domain (NTD), a hydrophobic transmembrane
domain (TMD), and a long cytoplasmic domain (CD) with two
predicted a-helical regions and two casein kinase II phosphoryla-
tion sites. (Fujita et al., 1997; Klimkait et al., 1990; Ruiz et al.,
2010a; Strebel et al., 1988; Terwilliger et al., 1989). Recently,
BST-2 (HM1.23, CD317, tetherin) was identiﬁed as a cellular
factor that restricts HIV-1 particle release and is antagonized by
Vpu (Neil et al., 2008; Van Damme et al., 2008). BST-2 is also an
integral membrane protein with a short N-terminal cytoplasmic
region, a transmembrane domain, and an ectodomain followed by
a glycophosphatidylinositol (GPI) anchor. The NTD of Vpu is
highly variable among HIV-1 subtypes in its amino acid sequence
and length. To date, no function has been associated with the
NTD. The Vpu TMD also exhibits sequence variability; however,ll rights reserved.
s).there are many residues that are highly conserved and, unlike the
NTD, the importance of the TMD in both CD4 surface down-
regulation and enhancement of virion release, speciﬁcally with
regards to species-speciﬁc recognition, interaction and antagonism
of BST-2, has been thoroughly demonstrated (Douglas et al., 2009;
Dube et al., 2009; Gupta et al., 2009; Hout et al., 2005; Kobayashi
et al., 2011; Kueck and Neil, 2012; Magadan and Bonifacino, 2012;
McNatt et al., 2009; Mitchell et al., 2009; Petit et al., 2011; Rong
et al., 2009; Ruiz et al., 2010b; Schubert et al., 1996; Shingai et al.,
2011; Skasko et al., 2012; Tiganos et al., 1998; Yoshida et al., 2011).
Additionally, the Nef protein encoded by some simian immunode-
ﬁciency virus (SIV) isolates has also been found to counteract
macaque BST-2, similar to Vpu antagonism of human BST-2 (Jia
et al., 2009; Ruiz et al., 2010b; Sauter and Kirchhoff, 2011; Sauter
et al., 2009; Yang et al., 2010; Zhang et al., 2009).
In light of the evidence supporting a species-speciﬁc recogni-
tion and counteraction of BST-2, several comprehensive analyses
of different Vpu proteins from various HIV-1 groups (M, N, O,
and P) have been conducted (Petit et al., 2011; Sauter et al., 2009,
2011; Yang et al., 2011). The results of these studies suggest
that different HIV-1 Vpu proteins may exhibit distinct anti-
BST-2 activity. Additionally, studies from our laboratory have
shown that a subtype B Vpu (US.HXB2) and subtype C
Vpu (C.96BW16B01) exhibit distinct structural and biological
A. Ruiz et al. / Virology 435 (2013) 395–405396properties that could potentially affect overall HIV-1 pathogenesis
(Hill et al., 2008; Pacyniak et al., 2005; Singh et al., 2003). Taken
together, these results strongly emphasize a necessity for devia-
tion from the longstanding practice of generalizing HIV-1 Vpu
properties based on an accumulation of results using laboratory
isolates. In lieu of this, our laboratory has been striving to
understand the physiological relevance of the distinctive proper-
ties exhibited by different Vpu subtypes.
Our laboratory has used the simian–human immunodeﬁciency
virus (SHIV) to study the role of various Vpu domains in virus
replication and pathogenesis in a macaque model of acquired
immune deﬁciency syndrome (AIDS). Previously, we showed that
a SHIV expressing a subtype C Vpu replicated less efﬁciently in T
cell cultures and caused a slower rate of CD4þ T cell loss
following inoculation into macaques, suggesting that the origin
of the Vpu could inﬂuence the rate of CD4þ T cell loss in vivo (Hill
et al., 2008). In the present study, we hypothesized that certain
Vpu domains were responsible for the decreased rate of CD4þ T
cell loss in macaques. To address this hypothesis, we constructed
two novel SHIVs in which we exchanged the NTD/TMD of subtype
B (US.HXB2) and C (C96.BW16B01) Vpu proteins. Our results
indicate that the loss of CD4þ T cells most likely correlates with
the NTD/TMD expressed, although the cytoplasmic domain is also
required for disease progression. These results emphasize that
Vpu proteins from different subtypes of HIV-1 can modulate the
rate of CD4þ T cell loss.Results
Chimeric Vpu proteins exhibit turnover rates similar to parental
Vpu proteins
The sequences of the parental and chimeric Vpu proteins
analyzed in this study are shown in Fig. 1. Similar to our previous
studies we engineered plasmids encoding the chimeric vpu genes
fused in frame to the gene for enhanced green ﬂuorescence
protein (eGFP) under the control of a CMV promoter. The Mr of
the four Vpu fusions proteins by SDS-PAGE is shown in Fig. 2A. In
order to determine if the exchange of domains resulted in altered
protein turnover, 293 cells were transfected with vectors expres-
sing each of the tagged Vpu proteins and at 48 h were subjected
to pulse-chase analysis (Fig. 2B and C). At the end of the 6 h chase
period, approximately 50%, 58%, 65%, and 60% of the protein
remained of subtype B Vpu (VpuSB), subtype C Vpu (VpuSC),
VpuBC, and VpuCB, respectively. These results indicate that
exchanging the domains of subtypes B and C Vpu proteins does
not signiﬁcantly modify the rate of protein turnover. These results
also identify the cytoplasmic domain as a determinant of the
differential molecular weights of VpuEGFP and VpuSCEGFP1 as we
have previously reported (Pacyniak et al., 2005).
As the vpu and env open reading frames overlap, we also
determined if the level of gp120 incorporated into virions was
similar to SHIVKU-1bMC33. C8166 cells were inoculated with 10
3
TCID50 of virus (10
3 TCID50) and incubated for ﬁve days. TheVpuB 1 MQPIPI-----VAIVALVVAIIIAIVVWSIVIIEYRKILR
Transmembrane
Domain
VpuBC 1 MQPIPI-----VAIVALVVAIIIAIVVWSIVIIEYRKLLR
VpuCB 1 MFSLIEKVDYRLGVGALIVAIIIAMIVWIIAYIEYRKILR
VpuC 1 MFSLIEKVDYRLGVGALIVAIIIAMIVWIIAYIEYRKLLR
Fig. 1. Sequences of the parental and chimcultures were radiolabeled with 35S-methionine and puriﬁed. The
results shown in Fig. 2D indicate that the level of gp120 in
the virions was similar for all four viruses, thus providing
evidence that the differences in virus replication were not due
to the Env incorporation into virions.
Chimeric Vpu proteins down-modulate CD4 surface expression
similar to parental subtype C Vpu
Previously, we showed that the subtype B (HXB2) Vpu was
more efﬁcient at down-modulating cell surface CD4 than several
subtype C Vpu proteins (Hill et al., 2008). Therefore, we analyzed
the ability of VpuBC and VpuCB to down-modulate surface CD4
expression. HeLa CD4þ cells were transfected with vectors
expressing each of the Vpu fusion proteins and at 48 h were
analyzed for CD4 surface expression by ﬂow cytometry. As shown
in Fig. 3, both VpuBC and VpuCB down-modulated CD4 expression
at levels that were similar to the subtype C Vpu protein and all
three were less efﬁcient at CD4 down-modulation compared to
the subtype B Vpu.
Intracellular localization of Vpu proteins is dictated by determinants
within the cytoplasmic domain
Following transfection of vectors expressing each of the Vpu
fusion proteins, cells were ﬁxed and examined by confocal
microscopy to determine the intracellular localization of the
chimeric Vpu proteins (Fig. 4). Similar to our previous studies,
cells co-transfected with vectors expressing the subtype B
VpuEGFP and DsRed–Golgi resulted in the VpuEGFP predomi-
nantly localized to the Golgi complex (Fig. 4A–D). Similarly, cells
transfected with vectors expressing VpuCBEGFP and DsRed–Golgi
resulted in the VpuCBEGFP also localized the Golgi complex
(Fig. 4E–H). However when cells were transfected with vectors
expressing VpuSCEGFP1 or VpuBCEGFP and DsRed-Mem, our
results indicated that these two proteins were more efﬁciently
transported to the cell surface (Fig. 4I–P). These results suggest
that the intracellular trafﬁcking of the chimeric Vpu proteins
correlated with the origin of the cytoplasmic domain, corroborat-
ing data we have presented previously supporting the existence
of sorting signals within the cytoplasmic domain (Pacyniak et al.,
2005; Ruiz et al., 2008).
SHIVs expressing chimeric Vpu proteins replicate more rapidly
than SHIVSCVpu
Our laboratory has generated a series of pathogenic chimeric
simian–human immunodeﬁciency virus (SHIV) molecular clones
in order to study the role of HIV-1 Vpu in pathogenesis. Our
results indicated that in addition to exhibiting differential bio-
physical properties in culture systems, the subtype B and subtype
C Vpu proteins had profoundly different effects on the rate of
CD4þ T cell loss in the SHIV/pig-tailed macaque model of disease
(Hill et al., 2008). In order to ascertain the role of each domain
(NTD/TMD and CD) in this phenomenon we engineered virusesQRKIDRLIDRLIERAEDSGNESEGEISALVEMGVEMGHHATWDVDDL
QKKIDRLIERIRERTEDSGNESEGDIEDLSTM-VDMDHLRLLDINN-
QRKIDRLIDRLIERAEDSGNESEGEISALVEMGVEMGHHATWDVDDL
QKKIDRLIERIRERTEDSGNESEGDIEDLSTM-VDMDHLRLLDINN-
eric Vpu proteins used in our studies.
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Fig. 2. Stability of the chimeric Vpu proteins and incorporation of Env into virus particles. Panel A: vectors expressing each of the Vpu proteins fused to EGFP were used to
transfect 293 cells. At 48 h, cells were starved for methionine/cysteine, radiolabeled with 35S-methionine/cysteine for 1 h, and then chased for 0, 3, and 6 h in cold DMEM
containing 100 methionine/cysteine. The cells were lysed with RIPA buffer and EGFP-containing proteins were immunoprecipitated using a rabbit anti-EGFP antibody as
described in the Materials and methods section. The immunoprecipitated proteins were collected on Protein A Sepharose beads, separated by SDS-PAGE (12% gel) and
visualized using standard autoradiographic techniques. Panel B. Pulse-chase analysis of the Vpu/EGFP fusion proteins. 293 cells were transfected with vectors expressing
VpuEGFP, VpuSCEGFP1, VpuBCEGFP, or VpuCBEGFP. At 48 h cultures were starved for methionine/ cysteine. The radiolabel was removed, washed and chased in medium
containing cold excess methionine/cysteine for 0, 3, and 6 h. EGFP-containing proteins were immunoprecipitated as described in the Materials and Methods. Panel C: the
percentage of each Vpu fusion protein from Fig. 2B remaining at 0, 3, and 6 h post chase. All conditions were run in duplicate, the pixel densities of each band determined
using ImageJ software, normalized to the hour 0 sample, and the average percent protein remaining calculated. Panel D: equivalent levels of SHIVKU-1bMC33, SHIVSCVpu,
SHIVVpuBC, or SHIVVpuCB were used to inoculate cultures of C8166 cells (10
4 TCID50). Cultures were incubated for ﬁve days, at which time cells were starved for methionine/
cysteine and radiolabeled overnight with 35S-methionine/cysteine. The virus-containing medium was collected and partially puriﬁed as described in the Materials and
methods section. The virus preparations were made lysed in 1RIPA buffer and viral proteins immunoprecipitated using an anti-SHIV serum. The immunoprecipitates
were collected on Protein A Sepharose beads, washed, and boiled in sample reducing buffer. The proteins were separated by SDS-PAGE and proteins visualized by standard
autoradiographic techniques. The samples were standardized for equivalent amounts of p27 and re-run on SDS-PAGE to compare levels of Env in virions.
A. Ruiz et al. / Virology 435 (2013) 395–405398expressing each of the chimeric Vpu proteins using the X4-tropic
molecular clone SHIVKU-1bMC33 backbone. We analyzed the growth
kinetics of SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC, and SHIVVpuCBPhase EGFP
VpuEGFP
VpuCBEGFP
VpuSCEGFP1
VpuBCEGFP
Fig. 4. Intracellular localization of the chimeric Vpu proteins. Expression of VpuEGFP, V
with vectors expressing each of the four fusion proteins and either DsRed2–Golgi or Ds
collected using laser scanning confocal microscopy as described in the Materials and m
Golgi. Panel A: phase contrast image of a cell expressing VpuEGFP and DsRed–Golgi. Pa
micrograph of a cell expressing DsRed–Golgi. Panel D: merge of panels B and C. Panel
contrast image of a cell expressing VpuCBEGFP and DsRed–Golgi. Panel F: ﬂuorescence
cell expressing DsRed–Golgi. Panel H: merge of panels F and G. Panels I–L: 293 cells co
cell expressing VpuSCEGFP1 and DsRed-Mem. Panel J: ﬂuorescence micrograph of a ce
DsRed-Mem. Panel L: merge of panels J and K. Panels M–P: 293 cells co-transfected wit
VpuBCEGFP and DsRed-Mem. Panel N: ﬂuorescence micrograph of a cell expressing VpuB
merge of panels N and O.
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Fig. 3. CD4 surface down-modulation by the parental and chimeric Vpu proteins.
HeLa CD4þ cells were transfected with plasmids expressing each of the parental
or chimeric Vpu proteins fused to EGFP. At 48 h, live cells were immunostained for
CD4 and ﬁxed. Cells were assessed for CD4 surface expression using ﬂow
cytometry. A mean ﬂuorescent intensity (MFI) ratio of transfected (EGFP positive)
to non-transfected cells (EGFP negative) was calculated for each sample with the
EGFP transfection control normalized to 1.0. Normalized ratios from three
separate experiments were averaged and the standard error calculated.following inoculation of C8166 cell cultures by measuring the p27
released into the supernatant. SHIVSCVpu replicated with reduced
kinetics in C8166 cultures compared to the parental SHIVKU-1bMC33,
which is similar to what we reported previously (Fig. 5A and B) (Hill
et al., 2008). We found that SHIVVpuBC replicated (i.e., released p27)
with delayed kinetics compared to the parental SHIVKU-1bMC33, but
was still signiﬁcantly more rapid than SHIVSCVpu. In contrast,
SHIVVpuCB replicated similar to SHIVSCVpu, reaching a higher plateau
around day nine. While these results suggest a role (structural or
functional) for both domains in viral replication kinetics, an empha-
sis of importance is consigned to the NTD/TMD region.Macaques inoculated with SHIVVpuBC have a more precipitous drop in
circulating CD4þ T cells than macaques inoculated with SHIVVpuCB
Three macaques were inoculated with SHIVVpuBC (W005, W018,
and W030) and three with SHIVVpuCB (W004, W007, and W013). The
circulating CD4þ T cells and viral loads were monitored for up to 26
weeks. The three macaques inoculated with SHIVVpuBC developed a
rapid loss of circulating CD4þ T cells and by two weeks post
inoculation the number of CD4þ T cells was less than 100 cells/ml
of blood. All three of these macaques maintained circulating CD4þ T
cell levels below 50 cells/ml of blood throughout the course of
their infections. Macaque W030 was euthanized at 10 weeks post
inoculation after developing an acute anemia. The hemoglobin and
hematocrit levels of this macaque decreased from 11 g/dl and 39%,
respectively, at 8 weeks post inoculation, to 2.3 g/dl and 9%, respec-
tively at 10 weeks post inoculation. Macaque W018 developed
a Candida infection and bloody diarrhea at week 25 and was
euthanized. Macaque W005 maintained low levels of circulatingDsRed2 Merge
puCBEGFP, VpuSCEGFP1, and VpuBCEGFP in 293 cells. 293 cells were co-transfected
Red2–Mem. At 48 h, cells expressing EGFP and DsRed2 were identiﬁed and images
ethods section. Panels A–D: 293 cells co-transfected with VpuEGFP and DsRed–
nel B: ﬂuorescence micrograph of a cell expressing VpuEGFP. Panel C: ﬂuorescence
s E–H: 293 cells co-transfected with VpuCBEGFP and DsRed–Golgi. Panel E: phase
micrograph of a cell expressing VpuCBEGFP. Panel G: ﬂuorescence micrograph of a
-transfected with VpuSCEGFP1 and DsRed-Mem. Panel I: phase contrast image of a
ll expressing VpuSCEGFP1. Panel K: ﬂuorescence micrograph of a cell expressing
h VpuBCEGFP and DsRed-Mem. Panel M: phase contrast image of a cell expressing
CEGFP. Panel O: ﬂuorescence micrograph of a cell expressing DsRed-Mem. Panel P:
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Fig. 5. Replication of the parental and chimeric Vpu proteins in C8166 cells.
Cultures of C8166 cells were inoculated with either SHIVKU-1bMC33, SHIVSCVpu,
SHIVVpuBC, or SHIVVpuCB as described in the Materials and methods section.
Aliquots of the culture medium were collected at 0, 3, 5, 7, 9, and 11 days post
inoculation and assayed for the presence of p27 antigen. Shown are the results of
two separate of growth curves.
A. Ruiz et al. / Virology 435 (2013) 395–405 399CD4þ T cells and was euthanized at 26 weeks post inoculation
(Fig. 6). The rate of circulating CD4þ T cell loss was not as rapid in the
macaques inoculated with SHIVVpuCB. At 2 weeks post inoculation the
circulating CD4þ T cells levels were 301, 402, and 1321 cells/ml of
blood, a time period when the SHIVVpuBC-inoculated macaques had
less than 100 circulating CD4þ T cells/ml of blood. For two of the
macaques (W004 and W013) in this group, there was a gradual drop
in circulating CD4þ T cells from 2 to 6 weeks post inoculation,
followed by a brief rebound. Macaque W007 also had a gradual loss
of CD4þ T cells, but this was not followed by a rise in CD4þ T cell
levels (Fig. 6). The circulating CD4þ T cells in macaquesW004, W007,
and W013 fell below 100 cells/ml at 5, 12, and 5 weeks post
inoculation, respectively. The rate of CD4þ T cell loss was statistically
signiﬁcant between SHIVKU-1bMC33 and SHIVVpuCB and between
SHIVSCVpu and SHIVVpuBC (po0.05). All three macaques were eutha-
nized at week 26 with low circulating CD4þ T cells but otherwise
in good condition. Macaques inoculated with SHIVKU-1bMC33 and
SHIVSCVpu were our previous study (Hill et al., 2008) except macaque
W006. This SHIVKU-1bMC33-inoculated macaque also developed a
massive loss of circulating CD4þ T cells with CD4þ T cells below
200 cells/ml within two weeks of inoculation and was euthanized at
26 weeks post inoculation.
Plasma virus loads in macaques inoculated with SHIVs expressing
chimeric Vpu proteins
The plasma viral loads from macaques infected with
SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC, or SHIVVpuCB are shownin Fig. 7. We previously reported that the plasma viral loads of
macaques inoculated with SHIVSCVpu were lower than those of
macaques inoculated with SHIVKU-1bMC33 (Hill et al., 2008). Here
we found that the plasma viral loads in macaques inoculated with
a SHIV expressing either chimeric Vpu were higher than those of
SHIVSCVpu and similar to SHIVKU-1bMC33-inoculated macaques. This
correlated with our growth curve data in C8166 cells that showed
that both chimeric Vpu viruses replicated better than the parental
SHIVSCVpu.
Macaques inoculated with chimeric viruses did not accumulate
changes within the Vpu gene throughout the duration of infection
We performed a sequence analysis of the vpu gene ampliﬁed
from PBMC DNA and from plasma viral RNA to determine the
stability and sequence variation of the chimeric Vpu proteins post
inoculation. Bulk sequence analyses of ampliﬁed vpu sequences
from PBMC DNA did not reveal consensus nucleotide changes at 4,
8, 12 or 26 (necropsy) weeks post inoculation. Similar results
were obtained following ampliﬁcation of vpu sequences from the
plasma viral RNA (data not shown).
The pathology in lymphoid organs at necropsy was similar to the
parental SHIVKU-1bMC33
We examined histological sections from tissues of macaques
inoculated with SHIVVpuBC or SHIVVpuCB at necropsy compared
with those from macaques inoculated with parental SHIVs. No
signiﬁcant histological lesions were observed in the 15 regions
of the brain and spinal cord (central nervous system; CNS),
the heart, liver, lungs, kidney, or pancreas of macaques inoculated
with the chimeric Vpu-expressing SHIVs (data not shown). The lack
of histological lesions in the CNS is not surprising, as the parental
SHIVKU-1bMC33 is not a neuropathogenic virus. We previously
reported that the histological lesions in SHIVSCVpu-inoculated maca-
ques were similar to those observed in SHIVKU-1bMC33-inoculated
macaques at necropsy (Hill et al., 2008). A comparison of the thymus
from the uninoculated, age-matched control macaque, a SHIVVpuBC-
inoculated macaque (W030) and a SHIVVpuCB-inoculated macaque
are shown in Fig. 8. Macaques inoculated with SHIVVpuBC, and
SHIVVpuCB showed severe depletion of the thymus compared to an
uninoculated control macaque (Fig. 8E). Similarly, the mesenteric
lymph nodes showed lymphoid depletion with no germinal centers
observed (Fig. 8D and F). Similar to macaques inoculated with highly
pathogenic CXCR4 using SHIVs, viral sequences could be detected in
most tissues examined (data not shown). These results indicate that
the pathology and virus distribution of the chimeric Vpu-expressing
SHIVs are similar to that of parental SHIVKU-1bMC33 and SHIVSCVpu.Discussion
Subtype C HIV-1 accounts for more than 50% of the HIV-1
infections worldwide, but paradoxically has lower replicative
ﬁtness in PBMC than in other subtypes of group M HIV-1 (Arien
et al., 2005, 2007; Ball et al., 2003; Essex, 1999; Hemelaar et al.,
2006; Takeb et al., 2004). Additional studies have suggested that
subtype C HIV-1 may be more efﬁciently secreted into vaginal or
cervical ﬂuids compared to subtypes A or D suggesting that
subtype C HIV-1 may be more efﬁciently transmitted than other
subtypes of HIV-1 (John-Stewart et al., 2005; Morrison et al.,
2010). Thus, identiﬁcation of genes involved may have implica-
tions for virus transmission and disease progression. Previously,
we showed that SHIVs that were genetically identical save the
Vpu protein expressed (either subtype B, SHIVKU-1bMC33; or sub-
type C, SHIVVpuSC) had different biological properties with respect
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Fig. 6. Circulating CD4þ T cell levels following inoculation of macaques with SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC, and SHIVVpuCB. Panel A: the levels of circulating CD4
þ
T cells in macaques (W006, 2000, CM4G, and CM4K) following inoculation with SHIVKU1b-MC33. Panel B: the levels of circulating CD4
þ T cells in three macaques (CX56,
CX57, and PLG2) following inoculation with SHIVVpuSC. Panel C: the levels of circulating CD4
þ T cells in three macaques (W005, W018, and W030) following inoculation
with SHIVVpuBC. Panel D. The levels of circulating CD4
þ T cells in three macaques (W004, W007, and W013) following inoculation with SHIVVpuCB.
A. Ruiz et al. / Virology 435 (2013) 395–405400to virus replication, CD4 surface down-regulation, intracellular
localization, and in the rate of CD4þ T cell loss in macaques (Hill
et al., 2008; Pacyniak et al., 2005). In the present study, we
constructed two SHIVs, SHIVVpuBC and SHIVVpuCB, in which we
exchanged the NTD/TMD of each Vpu to generate chimeric
proteins. Our results show that the rate of CD4þ T cell loss
correlated with the origin of the NTD/TMD region. That is,
macaques inoculated with SHIVs expressing a Vpu protein with
the subtype B NTD/TMD (SHIVKU-1bMC33 or SHIVVpuBC) presented
with rapid CD4þ T cell loss, having r100 CD4þ T cells/ml of
blood by two weeks post inoculation. The CD4þ T cell loss caused
by SHIVVpuBC was comparable to the parental SHIVKU-1bMC33 virus
with one macaque euthanized at 10 weeks due to severe anemia
and another at 26 weeks due to an opportunistic infection. In
contrast, the three macaques inoculated with SHIVVpuCB did not
develop circulating CD4þ T cell levels below 100 cells/ml of blood
until ﬁve to 12 weeks post inoculation and were euthanized at
approximately 26 weeks with low circulating CD4þ T cell
numbers (o50 cells/ml) but otherwise healthy.
A potential question that arises is whether or not there is a
structural basis for the differences in the rate of CD4þ T cell loss.
Comparison of the TMDs from the two parental proteins reveals
that of the 21 amino acids comprising the TMD, there are
differences at nine positions. As expected, the changes were both
conservative and hydrophobic in nature and it is possible that
several changes in concert could lead to the in vivo observations.
The amino acids recently shown to be important for interactions
of the Vpu TMD with the BST-2 TMD and the tryptophan thought
to be important in stabilizing the Vpu in the membrane were
conserved among these two Vpu proteins (Skasko et al., 2012).While we cannot state with certainty that the TMD is solely
responsible for the difference in the rate of CD4þ T cell loss in
macaques (or if the NTD also contributes), support for the TMD as
the major determinant is that the NTD of Vpu is the most variable
region of the protein among the different HIV-1 subtypes
(McCormick-Davis et al., 2000b) and that no biological property
has yet been assigned to this region of Vpu. However, the major
difference between the two proteins is that VpuSB has a short NTD
of ﬁve amino acids and with two prolines most likely assumes a
fairly rigid structure. In contrast, the VpuSC has a longer NTD of 11
amino acids containing several positive and negatively charged
residues. It should be noted that the longer N-terminal sequence
is unique to clade C Vpu proteins, particularly those isolated from
Africa, which was used in this study.
Based on our in vivo data we sought to determine what
quantitative in vitro biological property best correlated with the
rate of CD4þ T cell loss in macaques. With respect to CD4 down-
modulation, we previously reported that the VpuSC appeared to
be slightly less efﬁcient at reducing CD4 surface expression when
compared to the VpuSB (Hill et al., 2008). However, we observed
that both chimeric Vpu proteins were also slightly less efﬁcient at
reducing CD4 surface expression yet the SHIVVpuBC was highly
pathogenic (if not more so than the parental SHIVKU-1bMC33). Thus,
we concluded that the slight differences in CD4 down-modulation
could not differentiate between viruses that result in different
rates of CD4þ T cell loss. These results imply that the major
inﬂuence in the differences in pathogenesis caused by these
viruses is the enhanced virion release function. Both VpuSB and
VpuSC can overcome BST-2-mediated restriction of virion release
in HeLa cells (data not shown) and Vpu/eGFP fusion constructs of
Fig. 7. Plasma viral loads following inoculation of macaques with SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC and SHIVVpuCB. Panel A: plasma viral RNA levels in macaques (W006,
2000, CM4G, and CM4K) inoculated with SHIVKU-1bMC33. Panel B: plasma viral RNA levels in macaques (CX56, CX57, and PLG2) inoculated with SHIVVpuSC. Panel C: plasma
viral RNA levels in macaques (W005, W018, and W030) inoculated with SHIVVpuBC. Panel D: plasma viral RNA levels in three macaques (W004, W007, and W013)
inoculated with SHIVVpuCB. Samples were subjected to real-time RT-PCR and Taqman probe homologous to the SIV gag gene as described in the material and methods
section. Standard curves were generated using ﬁve dilutions of viral RNA of known concentration.
A. Ruiz et al. / Virology 435 (2013) 395–405 401both subtypes have been shown to down-regulate BST-2 surface
expression in the same cells (Van Damme et al., 2008). Addition-
ally, we previously showed that the pig-tailed BST-2 protein does
not interact with the VpuSB, but rather is restricted by the
SIVmac239 Nef protein expressed by all viruses used throughout
this study (Ruiz et al., 2010b). Thus, the in vitro assays measuring
Vpu/BST-2 interactions do not explain the differences in the
subtype C and B SHIVs. The results from the p27 growth curves
in C8166 cells show that both chimeric viruses replicated better
than the SHIVVpuSC and that SHIVVpuBC replicated better than
SHIVVpuCB. However, none of the viruses analyzed in this study
replicated as well as parental subtype B SHIVKU-1bMC33. Finally,
our results indicate that the CD determined if the Vpu was
efﬁciently expressed on the cell surface as the chimeric VpuBC,
which contained the subtype C CD, was efﬁciently expressed on
the cell surface similar to VpuSC. These data correlate with our
previous study in which we showed that the C-terminal domain
of the subtype B Vpu contained a sequence that retained the
majority of the Vpu protein in Golgi/trans Golgi compartments of
the cell (Pacyniak et al., 2005). Thus, of the in vitro biological
properties assessed prior to inoculation of macaques, it appears
that retention of Vpu in the intracellular compartments of the
cell was predicative of a faster rate of CD4þ T cell loss. While
speculative at this point, it suggests that more efﬁcient expres-
sion at the cell surface is inversely proportional to the rate
of CD4þ T cell loss in vivo. It will be of interest to determine if
SHIVs expressing Vpu proteins from other HIV-1 subtypes
that are primarily localized to intracellular compartments
also result in rapid CD4þ T cell loss similar to the VpuSB and
VpuBC.Materials and methods
Cells lines
The C8166 cell line was used to generate, and as the indicator
cells to measure infectivity and cytopathicity of the viruses used
in this study. C8166 cells were maintained in RPMI 1640,
supplemented with 10 mM Hepes buffer, pH 7.3, 2 mM gluta-
mine, 5 mg/ml gentamicin, penicillin–streptomycin (100 U/ml–
100 mg/ml), and 10% fetal bovine serum (FBS). The 293 cell line
was maintained in Dulbecco’s minimal essential medium (DMEM)
supplemented with 10% FBS and the antibiotics described above.
The HeLa CD4þ cell line was maintained in DMEM supplemented
with 10% FBS, the antibiotics listed above, and 1 mg/ml of G-418.
Construction of vectors expressing the chimeric Vpu proteins
Vectors expressing the subtype B (pcvpuegfp) and C (pcvpus-
cegfp1) Vpu proteins fused to enhanced green ﬂuorescent protein
(eGFP) have been previously described (Gomez et al., 2005;
Pacyniak et al., 2005; Singh et al., 2003). In order to construct
plasmids expressing subtype B and subtype C chimeric vpuegfp
fusion genes an EcoRV site was inserted into each parental vpu
gene expressed in a pcDNA3.1(þ) expression vector at the
interface between the putative transmembrane domain and
the cytoplasmic domain, using site-directed mutagenesis. The
N-terminal regions were excised from the parental plasmids
using KpnI and EcoRV restriction enzymes. The N-terminal region
fragments were ligated into the opposing digested vector. The
EcoRV sites were then removed using site-directed mutagenesis
Fig. 8. Comparison of the histopathology associated with SHIVVpuBC and SHIVVpuCB-
inoculated macaques with an uninfected, age-matched control macaque. Hematox-
ylin and eosin stains of sections from the thymus (Panels A, C, and E) and mesenteric
lymph node (Panels B, D, and F) from an uninfected age-matched macaque (Panels
A–B), a SHIVVpuBC infected macaque (Panels C–D), and a SHIVVpuCB-inoculated
macaque (Panels E–F).
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sequenced to ensure validity of the genes and that no other
mutations were introduced during the cloning process.
Construction of SHIVs expressing chimeric Vpu proteins
The derivation and pathogenicity of SHIVKU-1bMC33 and
SHIVSCVpu have been described (Hill et al., 2008;McCormick-
Davis et al., 2000a; Singh et al., 2003; Stephens et al., 2002). For
the construction of SHIVs expressing VpuBC and VpuCB, site-
directed mutagenesis was performed on the pGEM3zf(þ) vector
containing the tat, rev, vpu, and env from either SHIVKU-1bMC33 or
SHIVSCVpu, to introduce an EcoRV site at the interface between the
putative transmembrane domain and the cytoplasmic domain.
The DNA fragment containing the vpu cytoplasmic and env
regions was isolated by digesting each resulting plasmid with
EcoRV and KpnI restriction enzymes. Each fragment was gel-
puriﬁed and ligated into the opposing digested vector. The EcoRV
sites were then removed using site-directed mutagenesis and the
resulting plasmids were sequenced to ensure validity of the genes
and that no other mutations were introduced during the cloning
process. Each plasmid was then digested with KpnI and SphI
restriction enzymes and the resulting fragments were puriﬁed
and directly cloned into p3’SHIVKU-1bMC33 to yield p3’SHIVVpuBC
and p3’SHIVVpuCB. The resulting plasmids were sequenced to
ensure that the tat, rev, vpu, and env genes were intact. For the
production of pSHIVVpuBC and pSHIVVpuCB each 3’SHIV plasmid
was digested in conjunction with p5’SHIV-4 with SphI overnight,
puriﬁed, ligated, and used to transfect C8166 cells as previouslydescribed (Hout et al., 2006, 2005; McCormick-Davis et al., 2000a,
2000b; Singh et al., 2003; Stephens et al., 2002). Stocks
were prepared, titrated in C8166 cells and stored at 80 1C
until used.
Analysis of env content in virions
To determine if the levels of Env protein were different in the
viruses expressing chimeric Vpu proteins, equivalent levels of
SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC, or SHIVVpuCB were used to
inoculate cultures of C8166 cells (103 TCID50). Cultures were
incubated for 5 days, at which time cells were starved for
methionine/cysteine and radiolabeled overnight with 35S-methio-
nine/cysteine. The virus-containing medium was collected and
centrifuged at low speed to remove cellular debris. The virus-
containing supernatant was centrifuged through a 20% sucrose
cushion (2 h, 100,000 g) and the pelleted virus resuspended in
tissue culture medium (without serum). The virus preparation
was loaded on a 20–60% sucrose gradient and centrifuged for 18 h
at 100,000 g using an SW55Ti rotor. The virus-containing frac-
tions were identiﬁed by analysis of fractions for p27 antigen and
the virus-containing fractions were lysed in 1RIPA buffer and
viral proteins immunoprecipitated using an anti-SHIV serum that
we previously showed to immunoprecipitate viral p27 and gp120.
The immunoprecipitates were collected on Protein A Sepharose
beads, washed, and boiled in sample reducing buffer. The proteins
were separated by SDS-PAGE and proteins visualized by standard
autoradiographic techniques. The samples were standardized for
equivalent amounts of p27 and re-run on SDS-PAGE to compare
levels of Env in virions.
Laser scanning confocal microscopy analysis
293 cells were cultured on cover slips one day prior to being
transiently co-transfected with plasmids expressing either VpuEGFP,
VpuSCEGFP1, VpuBCEGFP, or VpuCBEGFP and either DsRed-monomer–
Golgi (with VpuEGFP and VpuCBEGFP) or DsRed–monomer–Mem
(with VpuSCEGFP1 and VpuBCEGFP) using PEI (Sigma). Following
transfection, cultures were maintained for 36–48 h before being
washed three times in PBS, and ﬁxed in 2% paraformaldehyde/PBS.
Cover slips were mounted in glycerol containing mounting media
(Slowfade Antifade solution A). A Nikon A1 confocal microscope was
used to collect 100 images with a 2 digital zoom, using EZ-C1
software. The pinhole was set to large (100 nm) for all wavelengths.
EGFP was excited using an argon 488 nm laser and viewed through
the FITC ﬁlter (525/25 nm) and the DsRed excited at 558 nm and
viewed through a 583 nm ﬁlter.
Pulse-chase analysis of chimeric Vpu proteins
293 cells were transfected with vectors expressing either the
VpuBCEGFP or VpuCBEGFP protein. At 48 h post transfection, the
medium was removed and cells were incubated in methionine/
cysteine-free medium for 2 h. The cells were then radiolabeled
with 200 mCi of 35S-Translabel (methionine and cysteine, MP
Biomedical) for 1 h. The radiolabel was chased in DMEM contain-
ing 100 unlabeled methionine/cysteine medium for 0, 3, and
6 h. Vpu proteins were immunoprecipitated using a rabbit anti-
EGFP serum and collected on protein A Sepharose beads on a
rotator for 18 h. Non-transfected 293 cells, starved, radiolabeled,
and chased for 0 h, served as negative control. Beads were washed
three times with 1 radioimmunoprecipitation buffer (RIPA:
(50 mM TrisHCl, pH 7.5; 50 mM NaCl; 0.5% deoxycholate; 0.2%
SDS; 10 mM EDTA), and the samples resuspended in sample
reducing buffer. Samples were boiled and the VpuEGFP fusion
proteins separated by SDS-PAGE (12% gel). Proteins were then
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ditions were run in duplicate, the pixel densities of each band
determined using ImageJ software, normalized to the hour 0
sample, and the average percent protein remaining calculated.
Analysis of CD4 surface down-modulation
For analysis of cell surface CD4 expression in the presence of
each chimeric Vpu protein, HeLa CD4þ cells were seeded into
each well of a 6-well tissue culture plate 24 h prior to transfec-
tion. Cells were transfected with vectors expressing each Vpu–
eGFP fusion protein described above. Cells transfected with a
vector expressing eGFP only were used as the control. At 48 h post
transfection, cells were removed from the plate using Ca2þ/
Mg2þ-free PBS containing 10 mM EDTA and stained with Phyco-
erythrin–Cyanine 5 (PE–Cy5) conjugated anti-CD4 antibody (BD
Bioscience). Cells were analyzed using an LSRII ﬂow cytometer
determining the mean ﬂuorescence intensity (MFI) of PE–Cy5 for
transfected (eGFP positive) and untransfected (eGFP negative)
cells within the same well. An MFI ratio was calculated for each
sample with the eGFP-only control normalized to 1.0. Normalized
ratios from at least three separate experiments were averaged
and the standard error calculated. Signiﬁcance was determined by
comparing all groups to the eGFP-only control using a Student’s
t-test, with po0.05 considered signiﬁcant.
Analysis of viral replication kinetics
Standard p27 assays (Zeptometrix Incorporated, SIV core
antigen kit) were used to assess release of viral particles
from cells infected with SHIVKU-1bMC33, SHIVSCVpu, SHIVVpuBC, or
SHIVVpuCB. Cultures of 10
6 C8166 cells or pig-tailed PBMC were
inoculated with 104 TCID50 of each virus stock for 4 h. At the end
of 4 h, the cells were centrifuged at 400 g for 10 min and the
pellet washed with 10 ml of medium. This was repeated two
additional times. The cells were resuspended in propagation
medium as described above and this was considered the 0 time
point of the assay. Cultures were incubated at 37 1C and aliquots
of the culture were removed at 0, 1, 3, 5, 7, 9, and 11 days post
infection, with fresh media added to the cultures at days 3, 6, and
9. The culture medium was separated from the cells by centrifu-
gation and assayed for p27 according to the manufacturer’s
instructions.
Macaques and inoculations
Three pig-tailed macaques (W005, W018, and W030) were
inoculated intravenously with 104 TCID50 of SHIVVpuBC. Macaque
W030 was euthanized in a moribund condition at 10 weeks post
inoculation. Macaques W005 and W018 were euthanized at
approximately 26 weeks post inoculation. Three pig-tailed maca-
ques (W004, W007, and W013) were inoculated intravenously
with 104 TCID50 of SHIVVpuCB. All three of these macaques were
euthanized in a healthy condition at approximately 26 weeks post
inoculation. We previously reported on the circulating CD4þ
T cell levels and virus loads in macaques inoculated with
pathogenic SHIVKU-1bMC33 and SHIVSCVpu (Hill et al., 2008; Singh
et al., 2003; Stephens et al., 2002). We also inoculated another
macaque with SHIVKU-1bMC33 (W006), which also developed a
profound loss of circulating CD4þ T cells as we have previously
reported for this virus. Macaques were housed in the AAALAC-
approved animal facility at the University of Kansas Medical
Center. EDTA-treated blood was collected weekly for 6 weeks,
then at 3-week intervals for the next 6 weeks, and thereafter at
monthly intervals.Processing of blood samples
The PBMCs were prepared by centrifugation on Ficoll–
Hypaque gradients as described previously (Joag et al., 1996).
Ten-fold dilutions of PBMCs (106 cells/ml) were inoculated into
replicated cultures of C8166 cells and were examined for devel-
opment of cytopathic effects as previously described (McCormick-
Davis et al., 2000a; Stephens et al., 2002). Alterations in circulat-
ing levels of CD4þ T lymphocytes after experimental inoculations
were monitored sequentially by ﬂow cytometric analysis. T cell
subsets were labeled with a commercially available anti-CD3/
CD4/CD8 cocktail (BD Biosciences) and compared to T lymphocyte
subsets from an uninfected macaque.
Processing of tissue samples at necropsy
At the time of euthanasia, animals were anesthetized by
administration of 10 mg/kg ketamine intramuscularly, followed
by an intravenous administration of sodium pentobarbital at
20–30 mg/kg. A laparotomy was performed on the animal exsan-
guinated by aortic cannulation. The chest was opened, the left
ventricle cannulated, the right atrium nicked, and the animal
perfused with 1 l of cold pyrogen-free Ringer’s saline. All aspects
of animal studies were performed according to the institutional
guidelines for animal care and use at the University of Kansas
Medical Center. At necropsy, tissues from the heart, kidney, liver,
lungs, axillary lymph nodes (LN), mesenteric LN, inguinal LN,
pancreas, salivary gland, small intestine, spleen, thymus, and
tonsil were ﬁxed in 10% neutral buffered formalin and embedded
in parafﬁn. Sections (5 mm) were stained with hematoxylin and
eosin for routine histological examination by a veterinary pathol-
ogist. In addition, the right half of the brain and spinal cord were
dissected into frontal, motor, parietal, temporal, and occipital
cortices, corpus callosum, thalamus, basal ganglia, midbrain, pons,
medulla, cerebellum, cervical, thoracic, and lumbar spinal cord,
and were processed as described above. Finally, sections of all
visceral and CNS tissues harvested were frozen in liquid nitrogen
for DNA and RNA isolation.
Sequence analysis of the Vpu gene
DNA isolated from several tissues harvested at necropsy was
used to amplify and sequence the vpu gene. For sequence analysis,
the PCR products from three separate reactions were separated by
electrophoresis on an agarose gel, isolated, and sequenced
directly. Cycle sequencing reactions were done using the BigDye
Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq
DNA polymerase, FS (PE Applied Biosystems, Foster City, CA) and
sequence detection was conducted with an Applied Biosystems
377 Prism XL automated DNA sequencer and visualized using the
ABI Editview program.
Plasma viral loads
Plasma viral RNA loads were determined on RNA extracted
from EDTA-treated plasma. The virus was pelleted and RNA
extracted using the QIAamp viral RNA kit (Qiagen). RNA samples
were analyzed by real-time RT-PCR using SIV gag speciﬁc primers
and a 5’FAM and 3’TAMRA labeled probe (Sigma) that was
homologous to the SIV gag gene. Standard curves were prepared
using a series of six 10-fold dilutions of viral RNA of
known concentration. The sensitivity of the assay was 100 RNA
equivalents/mm. Samples were analyzed in triplicate and the
number of RNA equivalents was calculated per milliliter of
plasma.
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